Publications by authors named "A Seshimo"
Low skeletal muscle mass reflects poor nutritional condition, which may impair the functional status and quality of life (QOL) of survivors of gastrectomy. The present cross-sectional study examined the association between a relative change in skeletal muscle mass and perceived postoperative health and QOL in patients with gastric cancer. The study comprised 74 patients (48 men and 26 women; median age, 68.
View Article and Find Full Text PDFArticle Synopsis
- - The debate over surgeries for proximal gastric cancer continues, with total gastrectomy (TG) as the standard approach, while alternatives like proximal gastrectomy (PG) and subtotal esophagectomy are also used in practice.
- - A study involving 1909 patients examined the types of gastrectomy performed, reconstruction techniques, and factors like stomach size and anti-reflux methods, revealing TG was most common (63.0%), followed by PG (33.4%).
- - Findings suggest that TG remains the preferred choice in Japanese clinical practice, but the size of the remnant stomach and the location of the esophageal stump significantly influence the reconstruction method after PG.
Background: The effects of various gastrectomy procedures on the patient's quality of life (QOL) are not well understood. Thus, this nationwide multi-institutional cross-sectional study using the Postgastrectomy Syndrome Assessment Scale-45 (PGSAS-45), a well-established questionnaire designed to clarify the severity and characteristics of the postgastrectomy syndrome, was conducted.
Aim: To compare the effects of six main gastrectomy procedures on the postoperative QOL.
Histological response of Grade 3 is relatively rare in gastric cancer patients but has recently been observed occasionally. We report the histological response of Grade 3 achieved by S-1/oxaliplatin(SOX)therapy. A 66-year-old man had suffered from epigastralgia when hungry.
View Article and Find Full Text PDFRationale: Primary malignant melanoma of the esophagus (PMME) is a very rare malignancy accounting for only 0.1% to 0.2% of all malignant esophageal lesions.
View Article and Find Full Text PDF